ArticleScientific reports2026
Lateral Flow Assay to detect CXCL10 as a diagnose-supporting biomarker for Polyomavirus-associated Nephropathy (PVAN) after kidney transplantation (KTx).
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney grafts, as the most transplanted organs, require intensive monitoring to ensure optimal transplant survival rates for patients. These rates can be jeopardized by severe, difficult-to-treat opportunistic infections such as polyomavirus, which can lead to polyomavirus-associated nephropathy (PVAN). There is an urgent need for non-invasive biomarker tests to narrow down the number of patients who require a transplant biopsy to confirm PVAN. The chemokine CXCL10 was significantly elevated in urine samples from kidney transplant recipients (KTR) with biopsy-confirmed PVAN compared to KTRs with a protocol biopsy found to be normal (114.8 ± 177.3 pg/ml, n = 22 vs. 11.4 ± 22.3 pg/ml, p < 0.0001, n = 45). Therefore, we developed a lateral flow assay (LFA) for the detection of PVAN with an area under the curve (AUC) of 0.832 according to receiver operating characteristic analysis as a point-of-care test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.